

**Supplementary Table S1.** Dose-response analysis of Juglone, PiB, and Wnt3a in MRC-5 cells based on MTT assay.

Compound	Concentration Tested	Cell Viability (% of Control)	Selected Experimental Dose	Rationale for Selection
<b>Juglone</b>	5 $\mu$ M	91.4 $\pm$ 2.1%		
	10 $\mu$ M	86.9 $\pm$ 1.8%		
	<b>20 <math>\mu</math>M</b>	<b>79.2 <math>\pm</math> 2.5%</b>	<b>20 <math>\mu</math>M</b>	Effective inhibition with minimal cytotoxicity
	30 $\mu$ M	65.3 $\pm$ 3.2%		
	40 $\mu$ M	49.7 $\pm$ 3.8%		
<b>PiB</b>	5 $\mu$ M	95.6 $\pm$ 1.5%		
	<b>10 <math>\mu</math>M</b>	<b>83.7 <math>\pm</math> 2.0%</b>	<b>10 <math>\mu</math>M</b>	Optimal balance of activity and cell survival
	20 $\mu$ M	66.5 $\pm$ 2.9%		
<b>Wnt3a</b>	25 ng/mL	98.2 $\pm$ 1.2%		
	<b>50 ng/mL</b>	<b>94.5 <math>\pm</math> 1.6%</b>	<b>50 ng/mL</b>	Strong $\beta$ -catenin activation with no cytotoxicity
	100 ng/mL	91.3 $\pm$ 2.3%		

**Note:** Cell viability was measured by MTT assay after 24 h exposure to each compound. Values are presented as mean  $\pm$  SD from three independent experiments. Selected doses were those producing  $\geq 80\%$  viability while showing strong pathway modulation in functional assays.